Education and Training

Comprehensive Protocol to Sample and Process Bone Marrow for Assesing Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Detection of measurable residual disease (MRD) is an important prognostic biomarker for refining risk assessment and predicting relapse in acute myeloid leukemia (AML). These comprehensive guidelines and recommendations with best practices for consistent and accurate identification and detection of MRD may aid in making effective AML treatment decisions.

2022 MFC-MRD workshop by Jacqueline Cloos and Angele Kelder at UMC Amsterdam.

Find the full slide deck of this interactive workshop on the role of MRD in AML and the use of MFC-MRD here.

Meetings and Workshops